This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Kentucky
Licensed Kentucky practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Kentucky buyers need their own professional license and NPI; the wholesaler license is the supplier’s obligation, not the purchaser’s.
Two Kentucky specifics are worth settling early. The wholesaler license a distributor holds here comes with a $25,000 surety bond, and the state’s only statute near this area, the 2017 Right to Try Act, is a terminal-illness access law that is regularly cited for more than it covers.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Kentucky? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Kentucky
ExaVeyra ships to licensed practices in all 50 states, Kentucky included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Kentucky professional license in good standing, verifiable through the Kentucky Board of Medical Licensure or Kentucky Board of Nursing license verification services.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Kentucky resale certificate through the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Kentucky licenses wholesale distribution of drugs through the Board of Pharmacy under KRS 315.402 and 201 KAR 2:105, and the same application reaches nonresident wholesalers shipping in, who additionally file their home-state permit, latest inspection report, and license verification. The distinguishing feature is the security: a $25,000 surety bond payable to the board, or an equivalent such as an irrevocable letter of credit or proof of insurance, with an exemption where the wholesaler already holds a comparable bond for a license in good standing in another state. Licenses renew by September 30 each year. The license sits with the distributor, not with the purchasing practice.
KRS 315.402; 201 KAR 2:105 · Kentucky Board of Pharmacy
Kentucky regenerative-medicine law
Kentucky has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Kentucky has enacted no statute addressing unapproved regenerative therapy, so federal law is the only layer. What it does have is the Right to Try Act, SB 21 of 2017, enacted as 2017 Ky. Acts chapter 65 and codified as new sections of KRS Chapter 217. That act reaches patients with a terminal illness using an investigational product that has completed phase 1 AND remains under investigation in an FDA-approved clinical trial, after a provider recommendation and written informed consent. Its one unusual feature is the operator: Kentucky defines health care provider to include licensed advanced practice registered nurses and physician assistants, not only physicians. It is an access statute with eligibility gates, not a regenerative medicine framework. HB 543, a 2026 bill modelled on the individualized-treatments acts in Kansas and Louisiana, was in the House Health Services Committee as of February 2026 and has not been enacted.
How this applies to exosomes
Kentucky has no stem cell authorization law like Florida, Texas, or Georgia, no disclosure law like California, and no documentation statute like Tennessee. The 2017 Right to Try Act is confined to terminal illness and to investigational products that have completed phase 1 and remain in an FDA-approved trial, which is a different subject from elective regenerative services, and it contains no definition that exosomes, as acellular extracellular vesicles, could be read into. Exosome products in Kentucky are therefore governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Kentucky practice
The practical planning point in Kentucky is the CAPA framework. An APRN-led practice needs a collaborating physician for prescribing until the four-year CAPA-NS exit is reached, and for controlled substances beyond that, so the collaboration is a standing relationship rather than paperwork filed once. Physicians and PAs verify through the Board of Medical Licensure, nurses and APRNs through the Board of Nursing.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Kentucky Board of Medical Licensure under KRS Chapter 311 may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. |
| NP / APRN | Kentucky APRNs practice under collaborative prescribing agreements with a physician in the same or a similar specialty: a CAPA-NS for nonscheduled legend drugs and a CAPA-CS for controlled substances, under KRS 314.042 and 201 KAR 20:057. After four years of prescribing under a CAPA-NS, an APRN may notify the Board of Nursing and prescribe nonscheduled drugs without one; exemption from the CAPA-CS runs through a separate, stricter board process. |
| PA | Physician assistants are licensed and regulated by the Kentucky Board of Medical Licensure and practice under physician supervision in the scope their supervising physician establishes; confirm current agreement requirements with the board. |
| RN | Registered nurses may perform delegated treatments within their scope under KRS Chapter 314 and under an order from a provider with authority to issue one. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
Kentucky expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. For an APRN the prescriptive side of that encounter runs through the CAPA framework until an exemption applies. Confirm current expectations with the Kentucky Board of Medical Licensure and the Kentucky Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
Kentucky does not codify a corporate practice of medicine prohibition of the Texas or New York kind; the doctrine surfaces through older case law and attorney general opinions, and professional entities with management services arrangements are the usual structures. Because the position is not a bright-line statutory rule, published summaries disagree with one another, so treat ownership structure as a question for Kentucky counsel and the Board of Medical Licensure rather than one a guide should answer with a percentage.
Cold chain into Kentucky
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Kentucky order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Louisville | Jefferson | Largest Kentucky market, with deep clinical and aesthetic coverage. |
| Lexington | Fayette | Second largest market, anchored by the University of Kentucky medical presence. |
| Covington | Kenton | Northern Kentucky market across the river from Cincinnati. |
| Bowling Green | Warren | South central market along the I-65 corridor. |
| Owensboro | Daviess | Western Kentucky market on the Ohio River. |
| Paducah | McCracken | Regional medical hub for far western Kentucky. |
- Kentucky orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every vial arrives with the manufacturer’s handling instructions and the Certificate of Analysis for its lot, and storage on arrival follows those instructions.
Practice types we supply in Kentucky
Kentucky licensing and verification
Kentucky Board of Medical Licensure
Licenses physicians and physician assistants.
Kentucky Board of Nursing
Licenses RNs and APRNs and administers the CAPA framework.
Kentucky Board of Pharmacy
Issues the wholesaler license under KRS 315.402.
Kentucky Department of Revenue
Sales and use tax registration and resale certificates.
Kentucky sourcing questions
- Does Kentucky have a stem cell law?
- No. Kentucky has enacted no stem cell authorization, disclosure, or documentation statute. The statute sometimes cited in its place, the 2017 Right to Try Act, covers terminal illness and investigational products that have completed phase 1 and remain in an FDA-approved clinical trial, which is a different subject entirely. Exosome products in Kentucky are governed by federal law, under which no exosome product is FDA approved for administration to humans.
- Are exosomes FDA approved?
- No. The FDA stated in its 2019 public safety notification that there are no FDA-approved exosome products, and that remains the case. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- What is unusual about Kentucky’s Right to Try Act?
- The operator. Kentucky defines health care provider to include licensed advanced practice registered nurses and physician assistants alongside physicians, so the provider who attests to the terminal illness and recommends the investigational product need not be a physician. The eligibility gates are otherwise conventional: terminal illness, phase 1 complete, still in an FDA-approved trial, and written informed consent. A 2026 bill, HB 543, would add an individualized-treatments pathway on the Kansas model; it was in committee as of February 2026 and has not been enacted.
- Can a Kentucky nurse practitioner prescribe without a physician agreement?
- For nonscheduled legend drugs, after four years. Kentucky APRNs begin under a CAPA-NS collaborative agreement with a physician under KRS 314.042, and after four years of prescribing may notify the Board of Nursing and continue without one. Controlled substance prescribing runs under a CAPA-CS, and its exemption is a separate, stricter board process with its own conditions.
- Does my Kentucky clinic need a wholesaler license to buy exosomes?
- No. The wholesaler license under KRS 315.402, with its $25,000 surety bond, is held by the distributor shipping into Kentucky, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How long does cold-chain shipping take to Kentucky?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Kentucky Board of Pharmacy, wholesaler licensure (accessed 16 October 2026)
- 2017 Ky. Acts ch. 65 (SB 21), Right to Try Act, enacted text (accessed 16 October 2026)
- Kentucky General Assembly, SB 21 (2017) bill record (accessed 16 October 2026)
- Kentucky General Assembly, HB 543 (2026) bill record (accessed 16 October 2026)
- Kentucky Board of Nursing, APRN prescriptive authority (accessed 16 October 2026)
- Kentucky Board of Medical Licensure (accessed 16 October 2026)
- Kentucky Department of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: Defines the field’s current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this Kentucky guide describes.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark EV characterization standard that MISEV2023 updates; together they define what a complete exosome characterization package on a supplier COA contains.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: ISEV position defining MSC-derived small extracellular vesicles, the product class behind the perinatal MSC-EV source material this page distinguishes from the investigational products Kentucky’s access statute covers.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.